

# Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call

April 10, 2017

LAVAL, Quebec, April 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced that it will conduct a live webcast of the Company's annual meeting of shareholders for the year-ended December 31, 2016.

The meeting will be held on Tuesday, May 2, 2017 at 9:00 a.m. ET at the Company's offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada, H7L 4A8. Only shareholders of record at the close of business on the record date of March 7, 2017, will be entitled to vote at the meeting.

A live webcast and audio archive of the presentation will be available on Valeant's corporate website on the Investor Relations page, under the Events and Presentations tab and via this URL: <http://ir.valeant.com/events-and-presentations>

## **First Quarter 2017 Financial Results Conference Call**

The Company also announced that it plans to release first quarter 2017 financial results on Tuesday, May 9, 2017. Valeant will host a conference call and live webcast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations portion of the corporate website before the start of the conference call.

## **Conference Call Details**

Date	Tuesday, May 9, 2017
Time	8:00 a.m. ET
Webcast	<a href="http://ir.valeant.com/events-and-presentations">http://ir.valeant.com/events-and-presentations</a>
Participant Event Dial-in	(877) 876-8393 (North America)
	(443) 961-0178 (International)
Participant Passcode	1757022
Replay Dial-in	(855) 859-2056 (North America)
	(404) 537-3406 (International)
Replay Passcode	1757022 (replay available until June 9, 2017)

### **About Valeant**

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com)

### **Contact Information:**

Elif McDonald  
514-856-3855  
877-281-6642 (toll free)  
[elif.mcdonald@valeant.com](mailto:elif.mcdonald@valeant.com)

### **Media:**

Renée Soto  
or  
Chris Kittredge/Jared Levy  
Sard Verbinnen & Co.  
212-687-8080

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2017-annual-meeting-of-shareholders-webcast-and-q1-2017-financial-results-conference-call-300437549.html>



### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**

